MMP9 and coronary artery disorder: A strength of the present study is the range and high number of characteristics and variables in the LSH cohort which makes this very beneficial for validation studies, especially the possibility of using not only other self-report data (SRH), but also biomedical data which are cross-sectional (IL-6, MMP-9) as well as prospective (CHD outcome 8 years later).